Ke Zhou

79 Qingchun Road
Hangzhou, 310003, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Tolerogenic dendritic cells induced by withdrawal of polyunsaturated fatty acid DHA and mTOR inhibitor PP242 attenuate allograft rejection.

Tolerogenic dendritic cells induced by withdrawal of polyunsaturated fatty acid DHA and mTOR inhibitor PP242 attenuate allograft rejection.

Journal: Acta biochimica et biophysica Sinica

Published: February 27, 2026

Engineering Immunoregenerative Therapy via an Immunomodulatory Binary Pharmacology Hydrogel Depot for Prolonged Allograft Survival.

Engineering Immunoregenerative Therapy via an Immunomodulatory Binary Pharmacology Hydrogel Depot for Prolonged Allograft Survival.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: October 21, 2025

Macrophage-delivered Nifuroxazide reprograms immunosuppressive microenvironment and synergizes with oxaliplatin for enhanced anti-hepatocellular carcinoma therapy.

Macrophage-delivered Nifuroxazide reprograms immunosuppressive microenvironment and synergizes with oxaliplatin for enhanced anti-hepatocellular carcinoma therapy.

Journal: Journal of nanobiotechnology

Published: October 02, 2025

Chemically engineered mTOR-nanoparticle blockers enhance antitumour efficacy.

Chemically engineered mTOR-nanoparticle blockers enhance antitumour efficacy.

Journal: EBioMedicine

Published: August 30, 2023

Loss of GLTSCR1 causes congenital heart defects by regulating NPPA transcription.

Loss of GLTSCR1 causes congenital heart defects by regulating NPPA transcription.

Journal: Angiogenesis

Published: December 06, 2022

DBF4 Dependent Kinase Inhibition Suppresses Hepatocellular Carcinoma Progression and Potentiates Anti-Programmed Cell Death-1 Therapy.

DBF4 Dependent Kinase Inhibition Suppresses Hepatocellular Carcinoma Progression and Potentiates Anti-Programmed Cell Death-1 Therapy.

Journal: International journal of biological sciences

Published: October 31, 2022

A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation.

A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation.

Journal: EBioMedicine

Published: October 19, 2022

Methylation site APC112043544 as a potential biomarker for post-transplant hepatocellular carcinoma recurrence.

Methylation site APC112043544 as a potential biomarker for post-transplant hepatocellular carcinoma recurrence.

Journal: Future oncology (London, England)

Published: May 03, 2022

Liver transplantation for Hepatocellular Carcinoma: A prognostic model incorporating pretransplant inflammatory cytokines.

Liver transplantation for Hepatocellular Carcinoma: A prognostic model incorporating pretransplant inflammatory cytokines.

Journal: Cytokine

Published: December 13, 2021

Polyploidy Spectrum Correlates with Immunophenotype and Shapes Hepatocellular Carcinoma Recurrence Following Liver Transplantation.

Polyploidy Spectrum Correlates with Immunophenotype and Shapes Hepatocellular Carcinoma Recurrence Following Liver Transplantation.

Journal: Journal of inflammation research

Published: October 22, 2021

Nanoparticle formulation of mycophenolate mofetil achieves enhanced efficacy against hepatocellular carcinoma by targeting tumour-associated fibroblast.

Nanoparticle formulation of mycophenolate mofetil achieves enhanced efficacy against hepatocellular carcinoma by targeting tumour-associated fibroblast.

Journal: Journal of cellular and molecular medicine

Published: March 27, 2020

Showing 1-11 of 11

Last Updated: 09/26/2026